newsfilter
← Latest News
GlobeNewswire·

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

  • BriaCell Therapeutics Corp. engaged Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, & market access potential for Bria-IMT in the US.
  • BriaCell appointed Kaleio to support brand strategies & customized commercial-readiness solutions for Bria-IMT.
  • Bria-IMT is currently under evaluation in BriaCell's ongoing pivotal Phase 3 study (NCT06072612) for metastatic breast cancer.
  • The therapy is not commercially approved & these engagements represent commercial-readiness steps pending successful clinical development & regulatory approvals.